Nektar Therapeutics
Q4 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +5.68%.
Did NKTR Beat Earnings? Q4 2025 Results
Nektar Therapeutics delivered a sharper-than-expected quarterly performance in Q4 2025, posting a loss of $1.78 per share against a consensus estimate of $3.50, a beat of 49.07%, while revenue of $21.81 million more than doubled analyst expectations of $10.41 million, even as the top line fell 25.3% year-over-year. The revenue decline reflects a deliberate strategic shift: following the December 2024 sale of its Huntsville manufacturing facility, Nektar's revenue base now rests almost entirely on non-cash royalties, stripping out product sales that padded prior-year figures. The quarter's net loss of $36.08 million also included $8.57 million in non-cash restructuring charges tied to declining San Francisco real estate values. On the pipeline front, positive Phase 2b proof-of-concept data for rezpegaldesleukin in alopecia areata and atopic dermatitis bolstered the company's clinical narrative, with Phase 3 initiation in atopic dermatitis targeted for Q2 2026. A securities fraud lawsuit alleging enrollment protocol violations in the REZOLVE-AA trial adds a layer of legal uncertainty, though Nektar enters the next phase with a substantially reinforced balance sheet after raising approximately $476 million in post-quarter financing.
- Revenue decline driven by elimination of product sales following December 2024 sale of Huntsville manufacturing facility
- G&A expense reduction due to decreased facilities and stock-based compensation costs
- Non-cash royalty revenue comprised nearly all of 2025 revenue
- Q4 2024 benefited from one-time $40.4 million gain on Huntsville facility sale
“2025 was a pivotal year for Nektar as we saw successful and transformative Phase 2 data readouts for rezpegaldesleukin. The data highlighted the promise and differentiation of our novel Treg mechanism in two inflammatory dermatological disease settings of atopic dermatitis and alopecia areata. In early 2026, we reported the 52-week treatment data for rezpegaldesleukin. These data provide hope that complete clearance of disease could be possible for patients with monthly and quarterly maintenance dosing of rezpegaldesleukin. With our strengthened financial position following the recent financing, we look forward to initiating our Phase 3 program in atopic dermatitis in June of this year, while we continue to advance our earlier TNFR2 agonist antibody and bispecific program toward the clinic.”
Nektar Therapeutics CEO, on the earnings call
Forward Guidance & Outlook
Nektar plans to commence Phase 3 studies for rezpegaldesleukin in moderate-to-severe atopic dermatitis in Q2 2026 (June). Additional topline data from the blinded 16-week treatment extension period in the REZOLVE-AA study in alopecia areata is expected in April 2026. The company will present 36-week maintenance data from the REZOLVE-AD study in the second half of 2026 and report topline data from a 24-week off-treatment period in REZOLVE-AA in Q4 2026, with 52-week off-treatment period data from REZOLVE-AD expected in Q1 2027. Initial data from a TrialNet-sponsored Phase 2 study in Stage 3 New Onset Type 1 Diabetes is expected in 2027. Preclinical data from the NKTR-0165 TNFR2 agonist antibody program will be presented at a scientific conference in the second half of 2026. The company's cash position was significantly bolstered post-quarter-end with approximately $476 million in proceeds from a secondary offering and at-the-market sales in February-March 2026.
NKTR YoY Financials
NKTR Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.